Search Results
Results found for "custom ligand development"
- Exploring pharmacological inhibition of G q/11 as an analgesic strategy
One potential solution is to develop analgesics that act at targets other than opioid receptors.
- 📰 GPCR Weekly News, July 24 to July 30, 2023
GPCR Binders, Drugs, and more Development of a V5-tag-directed nanobody and its implementation as an Discovery Industry Indivior Announces Q2/H1 2023 Financial Results Scientists Discover a New Way To Develop
- GPCR Therapeutics Expands Scientific Advisory Board
Jon Wigginton will provide scientific expertise to support the company’s research and clinical development
- Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ...
(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel
- Hear the sounds: the role of G protein-coupled receptors in the cochlea
The research of GPCRs in the cochlea is essential for the understanding of the cochlea development, hearing
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development
- GPCR Happy Hour – Boston, Sept 2025
decades of experience, their services include AI-driven target identification, target validation, assay development
- Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief ...
(Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization
- The microglial endocannabinoid system similarly regulated by lipopolysaccharide and interferon gamma
capacity of microglia to synthesize, degrade, and respond to cannabinoids which has implications for the development
- Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors
As a result, there is an ongoing need to develop novel approaches to monitor and to modulate GPCR activation
- A central alarm system that gates multi-sensory innate threat cues to the amygdala
The identification of unified innate threat pathways may provide insights into developing therapeutic
- Primary cilia and SHH signaling impairments in human and mouse models of Parkinson’s disease
Thus, increased SHH activity due to ciliary dysfunction may be required for the development of pathoetiological
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
(Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization
- Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...
, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development
- 📰 GPCR Weekly News, June 26 to July 2, 2023
Development, synthesis and evaluation of novel fluorescent Endothelin-B receptor probes. Developing a novel framework for structure-based pharmacophore model generation and selection.
- RAB-Symposium - Regulatory Autoantibodies Targeting GPCRs. September 15-16, 2022. Lübeck, Germany...
So far, numerous therapeutics targeting GPCRs have been developed, with a focus on small molecules and
- Orion Shares New Data on its Latest Best-in-Class Drug Candidate
June 2022 "Ottawa, Canada, May 10, 2022 — Orion Biotechnology Canada Ltd, a drug discovery and development
- Targeted Activation of G-Protein Coupled Receptor-Mediated Ca 2+ Signaling Drives Enhanced Cartilage
]i) signaling is a critical regulator of chondrogenesis, chondrocyte differentiation, and cartilage development a CNO dose- and frequency-dependent manner, and triggered the formation of cell condensations that developed
- Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...
, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development
- VAMP2: a crucial player in the delivery of MOR to the synapse
Through developing a high-resolution method, Hao Chen et al. directly visualized the fusion of vesicles Therefore, their comprehension is essential for developing new treatments for these disorders and advancing
- Pepducin-mediated G Protein-Coupled Receptor Signaling in the Cardiovascular System
We will discuss the historic context of pepducin development for each receptor, as well as the structural
- Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of...
It has begun to play important roles in drug development for complex diseases such as cancer, including
- Drug Discovery Picks Up the Pace, Stays on Target
A project to develop a perfect drug, or a drug that is as safe and effective as possible, may never begin
- Reflections on My PhD Journey: Lessons Learned
It challenges you to push your limits, adapt to unforeseen challenges, and develop habits that will serve
- Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AI
artificial intelligence (AI), machine learning, and the design of protein structures in the discovery and development
- G protein-coupled receptor kinase 2 is essential to enable vasoconstrictor-mediated arterial ...
signalling pathways that promote vascular smooth muscle cell (VSMC) proliferation, contributing to the development Considering VSMC GRK2 expression increases early in the development of hypertension, this highlights
- Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team
(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel
- Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone...
regarding the complex biology of the preproglucagon-derived hormones, their signaling, and the drug development
- The Bile Acid Membrane Receptor TGR5 in Cancer: Friend or Foe?
regulating proliferation, inflammation, adhesion, migration, insulin release, muscle relaxation, and cancer development
- Although the cannabinoid type-2 receptor (CB2) is highly expressed in the immune system, emerging...
The development of new CB2-related pharmacological and genetic tools, including the first small molecule

